Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey

Author:

Woopen Hannah12ORCID,Keller Maren2,Zocholl Dario23ORCID,Mittelstadt Suzana24,Barretina-Ginesta Maria-Pilar5678,Heinzelmann-Schwarz Viola910,Lafleur Judith1112,Kocián Roman131415ORCID,Baum Joanna12,Krabisch Petra216,Achimas-Cadariu Patriciu17ORCID,Vardar Mehmet Ali1819,Vergote Ignace2021ORCID,Nasser Sara122ORCID,Link Theresa223,Gil-Martin Marta824ORCID,Zwimpfer Tibor A.910ORCID,Leitner Katharina1225ORCID,Jedryka Marcin152627ORCID,Boxler Tamara28,Braicu Elena Ioana12,Sehouli Jalid12ORCID

Affiliation:

1. Department of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité—Universitätsmedizin Berlin, 13353 Berlin, Germany

2. North-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany

3. Institute of Biometry and Clinical Epidemiology, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité—Universitätsmedizin Berlin, 10117 Berlin, Germany

4. Department of Women’s Health, University Hospital Tübingen, 72076 Tübingen, Germany

5. Institut Català d’Oncologia, Medical Oncology Department, 17007 Girona, Spain

6. Precision Oncology Group, Institut d’Investigació Biomèdica de Girona, 17007 Girona, Spain

7. Medical Sciences Department, Universitat de Girona, 17003 Girona, Spain

8. Grupo Español de Investigación en Cáncer de Ovario (GEICO), 28003 Madrid, Spain

9. Department of Gynecology and Gynecologic Oncology, University Hospital of Basel, 4056 Basel, Switzerland

10. Swiss GO Trial Group (Swiss-GO), 4031 Basel, Switzerland

11. Department of Gynecology and Obstetrics, Ordensklinikum Barmherzige Schwestern Linz, 4020 Linz, Austria

12. Arbeitsgemeinschaft Gynaekologische Onkologie Austria (AGO Austria), 6020 Innsbruck, Austria

13. Department of Gynaecology, Obstetrics and Neonatology First Faculty of Medicine, Charles University and General University Hospital in Prague, 12 108 Prague, Czech Republic

14. General University Hospital in Prague, 12 808 Prague, Czech Republic

15. Central and Eastern European Gynecologic Oncology Group (CEEGOG), 128 51 Prague, Czech Republic

16. Department of Gynaecology and Obstetrics, Klinikum Chemnitz, 09116 Chemnitz, Germany

17. Institute of Oncology Prof. Dr. I. Chiricuta Cluj-Napoca, University of Medicine and Pharmacy Iuliu Hatieganu, 400015 Cluj-Napoca, Romania

18. Department of Gynecologic Oncology, Cukurova University, 01250 Adana, Turkey

19. Turkish Society of Gynecologic Oncology (TRSGO), Ovecler, 06450 Ankara, Turkey

20. Division of Gynaecological Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium

21. Belgium and Luxembourg Gynaecological Oncology Group (BGOG), 3000 Leuven, Belgium

22. Pan-Arabian Research Society of Gynecological Oncology (PARSGO), 13353 Berlin, Germany

23. Department of Gynecology and Obstetrics, Technische Universität Dresden, 01307 Dresden, Germany

24. Catalan Institute of Oncology—IDIBELL, L’Hospitalet-Barcelona, 08908 Barcelona, Spain

25. Department of Obstetrics and Gynecology, Innsbruck Medical University, 6020 Innsbruck, Austria

26. Gynecological Oncology Department, Wroclaw Medical University, 50-367 Wroclaw, Poland

27. Oncological Gynecology Department, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland

28. Frauenklinik Fürth, 90766 Fürth, Germany

Abstract

The aim of this survey was to increase the knowledge on the characteristics and health concerns of long-term survivors (LTS; survival > 5 years) after ovarian cancer in order to tailor follow-up care. This international survey was initiated by the NOGGO and was made available to members of ENGOT and GCIG. The survey is anonymous and consists of 68 questions regarding sociodemographic, medical (cancer) history, health concerns including distress, long-term side effects, and lifestyle. For this analysis, 1044 LTS from 14 countries were recruited. In total, 58% were diagnosed with FIGO stage III/IV ovarian cancer and 43.4% developed recurrent disease, while 26.0% were receiving cancer treatment at the time of filling in the survey. LTS who survived 5–10 years self-estimated their health status as being significantly worse than LTS who survived more than 10 years (p = 0.034), whereas distress also remained high 10 years after cancer diagnosis. Almost half of the cohort (46.1%) reported still having symptoms, which were mainly lymphedema (37.7%), fatigue (23.9%), pain (21.6%), polyneuropathy (16.9%), gastrointestinal problems (16.6%), and memory problems (15.5%). Almost all patients (94.2%) regularly received follow-up care. Specialized survivorship care with a focus on long-term side effects, lifestyle, and prevention should be offered beyond the typical five years of follow-up care.

Funder

German Ovarian Cancer Foundation

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3